## HCC Diagnosis: Imaging, Markers, and Diagnostic Criteria ### AASLD/EASL Diagnostic Criteria for HCC The diagnosis of hepatocellular carcinoma in cirrhotic patients relies on a combination of imaging and tumor markers, with specific size thresholds and imaging criteria. ### Diagnostic Algorithm for HCC in Cirrhosis ```mermaid flowchart TD A[Nodule detected in cirrhotic liver]:::outcome --> B{Nodule size?}:::decision B -->|< 10 mm| C[Surveillance ultrasound every 3-4 months]:::action B -->|10-20 mm| D{Imaging findings?}:::decision B -->|> 20 mm| E{Imaging findings?}:::decision D -->|Arterial enhancement + washout on 1 modality + AFP >400| F[HCC diagnosed]:::outcome D -->|Arterial enhancement on 1 modality only| G[Biopsy or follow-up imaging]:::action E -->|Arterial enhancement + washout on 1 modality| H[HCC diagnosed]:::outcome E -->|Arterial enhancement + washout on 2 modalities| I[HCC diagnosed]:::outcome E -->|Arterial enhancement only on 1 modality| J[Biopsy or follow-up]:::action ``` ### Key Diagnostic Points | Criterion | Requirement | Notes | |-----------|-------------|-------| | Nodule size 10–20 mm | 1 imaging modality + AFP >400 OR 2 modalities | AFP alone insufficient | | Nodule size > 20 mm | 1 imaging modality (arterial enhancement + washout) | Single modality sufficient | | AFP level | Supportive, not diagnostic | 30% of HCC are AFP-negative | | Biopsy | Required if imaging inconclusive | Confirms diagnosis in borderline cases | ### High-Yield: The Critical Error in Option 4 **A single imaging modality is NOT sufficient for HCC diagnosis in ALL cirrhotic patients regardless of size.** The AASLD criteria require: - **Nodules > 20 mm:** One imaging modality showing arterial phase enhancement AND washout is diagnostic - **Nodules 10–20 mm:** Either two imaging modalities OR one modality + AFP >400 ng/mL - **Nodules < 10 mm:** Surveillance only **Warning:** The statement in option 4 ignores the size-dependent diagnostic algorithm and incorrectly suggests that imaging alone is always sufficient, which violates AASLD/EASL guidelines. ### Key Point: AFP Limitations - **Sensitivity:** ~60% overall; lower in early HCC - **Specificity:** Moderate; elevated in cirrhosis, hepatitis, benign liver disease - **AFP-negative HCC:** ~30% of cases; more common in non-B, non-C cirrhosis - **AFP-L3:** More specific for HCC; useful for early detection and prognosis ### Clinical Pearl: AFP-L3 Significance AFP-L3 (lens culinaris agglutinin-reactive AFP) represents the fucosylated fraction of AFP and is: - More specific for HCC than total AFP - Elevated in ~70% of HCC cases - Useful for distinguishing HCC from benign liver disease - Prognostic marker: high levels associated with worse outcomes ### High-Yield: Imaging Modalities for HCC Dynamic imaging (CT or MRI) showing: - **Arterial phase enhancement:** Tumor blush during hepatic artery phase - **Washout:** Loss of enhancement in portal venous or delayed phase - Both features together = hallmark of HCC [cite:Harrison 21e Ch 81] [cite:Robbins 10e Ch 19] [cite:AASLD HCC Guidance 2018]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.